IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of ...

"Our robust pipeline, anchored by promising programs like our WRN and SIK inhibitors, and our ongoing collaboration with Lilly, continues to validate our approach and strengthen our position in ...

Behind those are a pair of androgen receptor antagonists and an internally developed WRN inhibitor that the biotech hopes could be aimed at MSI-high and other DNA repair–deficient cancers.

Eikon’s early-stage pipeline houses two androgen receptor antagonists and a WRN inhibitor dubbed EIK1005, which is being studied for its potential as a therapy for patients with microsatellite ...

In addition, Eikon’s early-stage pipeline features two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) that is being studied for its potential as a therapy for ...

"Our robust pipeline, anchored by promising programs like our WRN and SIK inhibitors, and our ongoing collaboration with Lilly, continues to validate our approach and strengthen our position in the ...

Eikon Therapeutics Inc. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Kinoteck Therapeutics Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

US-based biotech Eikon Therapeutics has raised $350.7m in funding to advance its portfolio of cancer candidates. The company’s lead asset, EIK1001, is a systemically administered Toll-like ...